Product Name: PAK1 (245-431) pT427+pY429
Product Number: PE-04AWT99
| Size: | 200 µg | Price: | 40.00 | |
| 1 mg | $US | 71.00 |
Peptide Name: PAK1 (245-431) pT427+pY429
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T427 and Y429 phosphorylation are predicted to be inhibitory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VG-pT-P-pY-WM
Peptide Modifications N Terminus: acetyl
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T427 and Y429 phosphorylation are predicted to be inhibitory for phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: VG-pT-P-pY-WM
Peptide Modifications N Terminus: acetyl
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1228.2 Da
Peptide Purity Percent after Synthesis and Purification: >70
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Stable as powder
Peptide Purity Percent after Synthesis and Purification: >70
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Storage Stability: Stable as powder
Scientific Background: PAK1 is a protein-serine/threonine kinase that is a member of the STE group of protein kinases in the STE20 family, and PAKA subfamily. This kinase is highly expressed and widely distributed in most tested human tissues. PAK1 has been implicated in the regulation of cytoskeletal organization, and cell proliferation and survival, morphology, motility and transformation. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK1 releases monomers from the autoinhibited dimer, enables phosphorylation at T423 and activation of its phosphotransferase activity. It is also activated by binding to GTP-bound Cdc42, independent of the phosphorylation state of T423. Phosphorylation of S144, S149, and T423 increases PAK1's phosphotransferase activity, whereas phosphorylation of T84 (by OXSR1) and Y212 inhibits its phosphotransferase activity. Phosphorylation of S21 inhibits binding of Nck and PIX. PAK1 may be a therapeutic target in B-Raf wild-type melanoma. Knockdown of PAK1 has been shown to inhibit the proliferation of mutant KRAS colon cancer cells.
© Kinexus Bioinformatics Corporation 2017